Bortezomib – 10 mg

Brand:
Cayman
CAS:
179324-69-7
Storage:
-20
UN-No:
Non-Hazardous - /

Bortezomib is a dipeptide boronic acid derivative that reversibly inhibits the 20S proteasome (Ki = 0.6 nM).{29724} It binds the β5-subunit of the 20S proteasome and selectively inhibits chymotryptic activity.{29723,29722,28244} In part by blocking the degradation of tumor-suppressing and proapoptotic proteins, bortezomib drives cell cycle arrest and apoptosis in cancer cell lines and has applications in multiple myeloma and certain lymphomas, as well as other types of cancer.{29724,29725} Proteasome inhibitors, including bortezomib, have potential in combination therapy with chemotherapy and radiation therapy against cancer.{29101,27757,28240,24628}  

 

Available on backorder

SKU: 10008822 - 10 mg Category:

Description

A dipeptide boronic acid derivative that reversibly inhibits the 20S proteasome (Ki = 0.6 nM); drives cell cycle arrest and apoptosis in cancer cell lines and has applications in multiple myeloma and certain lymphomas, as well as other types of cancer


Formal name: B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid

Synonyms:  LDP-341|MG-341|MLN341|NSC 681239|PS-341

Molecular weight: 384.2

CAS: 179324-69-7

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cell Biology|Proteolysis|Ubiquitin/Proteasome System